Intraorbital corticosteroid injection for orbital reactive lymphoid hyperplasia

dc.contributor.authorAndrew, N.
dc.contributor.authorKearney, D.
dc.contributor.authorSelva-Nayagam, D.
dc.date.issued2013
dc.description.abstractPURPOSE The purpose of this study is to assess the utility of intraorbital injection of triamcinolone acetonide as a primary treatment option for orbital reactive lymphoid hyperplasia (RLH). PATIENTS AND METHOD Retrospective, single-centre, interventional case series. RESULTS Intraorbital injection of triamcinolone acetonide was associated with complete resolution of all symptoms and signs in four cases (80%). This was achieved with a single injection in two cases and with two injections in another two cases. Radiological resolution was confirmed in one case. One case developed bilateral multifocal orbital RLH lesions 1 month after the second injection. CONCLUSION Intraorbital injection of corticosteroid may be a useful treatment option for orbital RLH, and may have a role as a first-line therapy in RLH of the anterior orbit. A significant proportion of patients may require repeat injections to achieve resolution. A larger prospective study is required to validate our findings.
dc.description.statementofresponsibilityNH Andrew, D Kearney and D Selva
dc.identifier.citationEye, 2013; 27(4):561-563
dc.identifier.doi10.1038/eye.2012.288
dc.identifier.issn0950-222X
dc.identifier.issn1476-5454
dc.identifier.orcidSelva-Nayagam, D. [0000-0002-2169-5417]
dc.identifier.urihttp://hdl.handle.net/2440/79796
dc.language.isoen
dc.publisherNature Publishing Group
dc.rights© 2013 Macmillan Publishers Limited All rights reserved
dc.source.urihttps://doi.org/10.1038/eye.2012.288
dc.subjectreactive lymphoid hyperplasia
dc.subjectlymphoproliferative disorders
dc.subjectcorticosteroid
dc.subjectdrug therapy
dc.subjectorbital disease
dc.titleIntraorbital corticosteroid injection for orbital reactive lymphoid hyperplasia
dc.typeJournal article
pubs.publication-statusPublished

Files